title: Diagnostic significance of FDG-PET and argyrophilic nucleolar organizer regions (AgNORs) in oral squamous cell carcinoma.
abstract: Neoadjuvant chemoradiotherapy has played an important role in preserving organs and functions in patients with oral squamous cell carcinoma (SCC). To determine whether further operation after chemoradiotherapy is necessary, accurate evaluation of residual tumour cells after treatment is essential. We investigated the usefulness of regional fluorodeoxyglucose (FDG) uptake in combination with histochemical expression of AgNORs obtained from pretreatment biopsy specimens to assess residual tumours after intraarterial chemoradiotherapy. Standardized uptake value (SUV: pretreatment, pre-SUV; post-treatment, post-SUV) was calculated to determine the changes of FDG uptake in the tumour before and after chemoradiotherapy. Four out of 20 patients with oral SCCs showed residual tumour cells after treatment. Tumours with higher post-SUVs (> or =4.0) and higher AgNORs scores (> or =5.0) had significantly higher incidences of residual viable tumour cells after chemoradiotherapy (P=0.001). The results suggest that the combination of FDG-PET with AgNORs score is an excellent index for determining the optimal management of each patient following neoadjuvant chemoradiotherapy.
authors.affiliation: Department of Dentistry and Oral Surgery, Fukui Medical University, Fukui 910-1193, Japan. mikikon@fmsrsa.fukui-med.ac.jp
authors.forename: Mikiko
authors.initials: M
authors.lastname: Nakamura
authors.forename: Kazuo
authors.initials: K
authors.lastname: Sano
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Kitagawa
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Ogasawara
authors.forename: Sadahiko
authors.initials: S
authors.lastname: Nishizawa
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Yonekura
mesh_terms: D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000628:therapy; D020360:Neoadjuvant Therapy; D018365:Neoplasm, Residual; D009697:Nucleolus Organizer Region / Q000473:pathology; D011379:Prognosis; D019275:Radiopharmaceuticals; D016622:Silver Staining; D014055:Tomography, Emission-Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18